M
MetaVia Inc. (MTVA)
NCM – Real vaqt narxi. Valyuta: USD
0.97
-0.07 (-6.73%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.00
+0.03 (3.09%)
Bozor oldidan: May 13, 2026, 7:02 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.97
-0.07 (-6.73%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.00
+0.03 (3.09%)
Bozor oldidan: May 13, 2026, 7:02 AM EDT
MetaVia Inc., klinik bosqichdagi biotexnologiya kompaniyasi, kardiyometabolik kasalliklarni davolash uchun yangi farmatsevtika vositalarini ishlab chiqishga qaratilgan. Kompaniya DA-1241 ni ishlab chiqadi, bu yangi G-protein-bog'langan retseptor 119 agonisti bo'lib, uni yagona va/yoki kombinatsiyalangan terapiya sifatida ishlab chiqish imkoniyati mavjud. Ushbu preparat metabolik disfunksiya bilan bog'liq steatohepatitni davolash uchun 2a fazali klinik sinovdan o'tmoqda, shuningdek, 2-toifali diabet mellitusni davolash uchun 1-fazali klinik sinovni yakunlagan; va DA-1726, GLP-1 retseptor va glyukagon retseptorining qo'sh agonisti sifatida ishlaydigan yangi oksintomodulin analogi, u semirishni davolash uchun 1-fazali sinovda. Uning terapevtik dasturlari orasida o'rtacha COVID-19 bilan kasallangan bemorlarni davolash uchun niklosamidning patentlangan og'iz orqali yuboriladigan shakli bo'lgan ANA001; diabetik nevropatiyani davolash uchun NB-01; kognitiv buzilishlarni davolash uchun NB-02; va dislipidemiyani davolash uchun Gemcabene mavjud. Kompaniya Gemcabene ni tadqiq qilish, ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha Pfizer Inc. bilan; va DA-1241 va DA-1726 ni ishlab chiqarish bo'yicha yagona ishlab chiqaruvchi Dong-A ST bilan litsenziya shartnomasiga ega. Kompaniya ilgari NeuroBo Pharmaceuticals, Inc. nomi bilan tanilgan va 2024-yil noyabr oyida MetaVia Inc. nomini olgan. MetaVia Inc.ning shtab-kvartirasi Kembrijda, Massachusets shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Mi-Kyung Kim | Chief Scientific Officer |
| Dr. W. Christopher Fang M.D. | Consulting Chief Medical Officer & Advisor |
| Mr. Hyung Heon Kim | CEO, President & Director |
| Mr. Marshall H. Woodworth | Chief Financial Officer |
| Mr. Michael C. Pine | Senior Vice President of Business Development Advisor |
| Mr. Robert Homolka | Senior Vice President of Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 8-K | mtva-20260511x8k.htm |
| 2026-04-27 | DEF 14A | ny20067174x2_def14a.htm |
| 2026-04-27 | ARS | ny20067174x3_ars.pdf |
| 2026-04-15 | PRE 14A | ny20067174x1_pre14a.htm |
| 2026-04-10 | 8-K | mtva-20260410x8k.htm |
| 2026-04-03 | S-8 | tm269393d2_s8.htm |
| 2026-03-26 | 8-K | mtva-20260326x8k.htm |
| 2026-03-18 | 8-K | mtva-20260318x8k.htm |
| 2026-01-27 | 8-K | mtva-20260123x8k.htm |
| 2026-01-15 | S-1MEF | tm2528002d20_s1mef.htm |